QIM
ALNY icon

Quest Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Quest Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-3,580
Closed -$280K – 128
2014
Q3 		$280K Hold
3,580
– – 0.03% 183
2014
Q2 		$226K Sell
3,580
-380
-10% -$22.6K 0.02% 203
2014
Q1 		$266K Buy
+3,960
New +$307K 0.03% 196

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Quest Investment Management's ALNY Position: Q4 2014 in Review

Quest Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2014, closing a stake of 3,580 shares — an estimated $280K sold.

Quest Investment Management first reported a position in ALNY in Q1 2014 and held it in 3 quarters. The position peaked at $280K in Q3 2014. 216 funds tracked by Wall St. Rank hold ALNY as of Q4 2014.

  • Quest Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Quest Investment Management sold 3,580 Alnylam Pharmaceuticals shares in Q4 2014, an estimated $280K.
  • Quest Investment Management first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 3 quarters.
  • Quest Investment Management's Alnylam Pharmaceuticals position peaked at $280K in Q3 2014.
  • 216 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2014.

Based on Quest Investment Management's 13F filing for Q4 2014, filed 12 Feb 2015.